Tertiary Hyperparathyroidism in Patient with End-Stage Chronic Renal Disease
DOI:
https://doi.org/10.66266/inajemd.v2i1.39Keywords:
Renal disease, hyperparathyroidism, calcium homeostasisAbstract
Mineral and bone disorder is frequently associated with chronic kidney disease (CKD) which starts early and worsens with renal progression. This condition depends on calcium and phosphate metabolism which will change parathyroid hormone (PTH) release. Understanding the pathophysiology of both secondary and tertiary hyperparathyroidism can reduce the development of its complications, such as renal osteodystrophy and cardiovascular disease. To describe a case of hypercalcemia patient caused by tertiary hyperparathyroidism with end-stage renal disease (ESRD) who underwent continuous ambulatory peritoneal dialysis (CAPD). A 50-years old patient was consulted for treatment of hyperparathyroidism due to mineral bone disease-related CKD. The patient has high levels of serum calcium, phosphate, and parathyroid hormone levels. She has already taken a phosphate binder and does CAPD 4 times daily. She underwent several radiology tests and knew that there was enlargement of her parathyroid glands. Based on that, she underwent parathyroidectomy with implantation. Until now, we still need to evaluate the changes in serum calcium, phosphate, and PTH level after the surgery. Hyperparathyroidism is a condition related to disturbance in calcium and phosphate homeostasis in CKD patients. Many factors contribute to the development of its progression. Early recognition and holistic treatment will be the most important thing to reduce the complication of hyperparathyroidism in CKD patients.
Downloads
References
1. Moe SM, Drüeke T, Lameire N, Eknoyan G. Chronic kidney disease-mineral bone disorder: a new paradigm. Adv in Chronic Kid Dis. 2007;14:3-12.
2. Uhlig K, Berns, JS, Kestenbaum B, et al. KDOQI U.S. commentary on the 2009 KDIGO clinical practice guideline for the diagnosis, evaluation, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Am J Kidney Dis. 2010;55:773-99.
3. Felsenfeld A, Silver J. Pathophysiology and clinical manifestations of renal osteodystrophy. In: Olgaard K, ed. Clinical guide to bone and mineral metabolism in CKD. New York, NY: National Kidney Foundation; 2006:31-41.
4. Ketteler M, Petermann AT. Phosphate and FGF 23 in early CKD: on how to tackle an invisible foe. Nephrol Dial Transplant. 2011;26:2430-2.
5. Kidney Disease Outcomes Quality Initiative (KDOQI). KDOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(suppl 3):S1S170.
6. Ho LY, Wong PN, Sin HK, Wong YY, Lo KC, et al. Risk factors and clinical course of hungry bone syndrome after total parathyroidectomy in dialysis patients with secondary hyperparathyroidism. BMC Nephrol. 2017;18: 12.
7. Boeckler P, Grunenberger F, Ruellan A, Vignon F, Weber JC, et al. Hungry bone syndrome after surgical treatment of severe primary hyperparathyroidism: about 3 cases. Ann Endocrinol. 2002; 63: 8-12.
8. Brasier AR, Nussbaum SR. Hungry bone syndrome: clinical and biochemical predictors of its occurrence after parathyroid surgery. Am J Med. 1988; 84: 654-660.
9. Mittendorf EA, Merlino JI, McHenry CR (2004) Post-parathyroidectomy hypocalcemia: incidence, risk factors, and management. Am Surg. 2004; 70: 114-119.
10. Van der Plas WY, Vogt L, Kruijff S: Advances in the diagnosis and management of secondary and tertiary hyperparathyroidism. In: Shifrin A (Ed.) Advances in Treatment and Management in Surgical Endocrinology. Elsevier Inc, Amsterdam, 2019, p. 326.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 InaJEMD - Indonesian Journal of Endocrinology Metabolism and Diabetes
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors retain copyright and grant the Indonesian Journal of Endocrinology, Metabolism and Diabetes (InaJEMD) the right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
© Indonesian Journal of Endocrinology, Metabolism and Diabetes (InaJEMD). Published by the Indonesian Society of Endocrinology (PERKENI).
